Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
about
Clinical roles of the aberrantly expressed lncRNAs in lung squamous cell carcinoma: a study based on RNA-sequencing and microarray data mining.Epithelial-mesenchymal plasticity and circulating tumor cells: Travel companions to metastases.Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes.Epithelial-mesenchymal plasticity in circulating tumor cells.Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer.Biology and clinical significance of circulating tumor cell subpopulations in lung cancerPD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients after first-line treatment option: systems assessment.Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer.Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors.A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry.Molecular characterization and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer.Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients.Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology.Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration.Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.Is minimal residual disease a convincing tool to determine the treatment duration of immune checkpoint inhibitors?Quantification of altered tissue turnover in a liquid biopsy: a proposed precision medicine tool to assess chronic inflammation and desmoplasia associated with a pro-cancerous niche and response to immuno-therapeutic anti-tumor modalities.Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors.Prospects for new lung cancer treatments that target EMT signaling.Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer.Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer.Circulating Tumor Cells: Markers and Methodologies for Enrichment and Detection.Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system?Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.Classifying circulating tumor cells to monitor cancer progression.Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy.Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy.Multimodal detection of PD-L1: reasonable biomarkers for immune checkpoint inhibitorLiquid biopsy of cancer: a multimodal diagnostic tool in clinical oncologyThe Prognostic Role of Circulating Tumor Cells (CTCs) in Lung CancerCurrent landscape of immune therapy in treatment of solid tumours, with future opportunities and challenges
P2860
Q36395226-2ECB1CB1-F3D3-4E04-833B-53605BE26D5DQ38838108-C9064420-C580-408D-A447-0EE04D916DA6Q39045171-0C514A49-A247-4996-B7E8-E55FCEC687E1Q39053335-D0F2736F-E1A0-4FAF-8BCE-93098CBBC9FCQ41605016-60092D4D-9EA5-4118-99BD-EAD35DFCAA7CQ41605032-ADA353CB-D404-4FCC-9090-0A5F5BDB3154Q41708775-73D4E2BA-DB3A-4F15-96CD-859893C26D7DQ42314661-49CE4F6A-8E2A-45D4-8AC9-B9463F26B553Q42329095-7742D7EA-0412-49A6-BAFF-8B7D7CBA52A8Q42700740-966D47F4-5E2B-4B7D-95A7-3ACE6737F244Q47104764-AE94DA42-4A75-46A3-B9FB-412ECCB7F435Q47110464-94209C73-FAEF-4A65-99BC-A9BA82888E9EQ47111652-B770A941-0225-48E0-A5CE-E9C810C524AEQ47153925-E201A339-41F6-4422-9484-4B71D516DF9DQ47354317-EE83DBEC-2978-44DB-8ECA-8044A8A57E4BQ47861831-71BAAB5C-D134-4FE6-BAA9-849E11ED33C4Q48068904-35691E66-8AF4-4446-8F0D-57D7664A038FQ48206682-98758D2F-6F65-441B-8DF7-C740770DF3E9Q48227716-D2A14BC3-6F98-4C8D-9ECC-BCAFC4908E7BQ48271468-258CA56C-EFEB-4E08-8DA2-DB66C2142260Q49380125-7C879814-3E3E-4D07-8DF6-A14E72975D9CQ50129978-52BB78FD-C1BE-438A-8CBF-C490A4FCAEA5Q50199981-A411E1F6-88A8-4678-A94F-0DC5B0EF78F9Q50205430-EE1B623D-E698-4821-A55B-F47A4E11FD87Q50433337-E9A50A5C-134E-4FB8-AF3E-15B8EB49CA66Q53097632-63D76BAE-D87E-40B5-A445-299FF84B38F1Q53755908-47DDEED2-545C-4695-809D-B88B0057B8D8Q55071620-62254217-FDCA-43D1-98EF-07607C4052DAQ55398181-2E81E744-31F2-45CD-A857-02D5A020BFE8Q57494139-F33222BD-B2F0-438D-B5DD-8D7C2089190EQ58695249-C8ED1EF1-CD5B-406A-9A09-140844C5F437Q58781611-D56C55C3-1AC2-4AC2-867E-FD37A7CA481AQ59135385-A42032CF-A03C-49E2-B38E-CDFA7CDC8EE9
P2860
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Monitoring PD-L1 positive circ ...... h the PD-1 inhibitor Nivolumab
@en
type
label
Monitoring PD-L1 positive circ ...... h the PD-1 inhibitor Nivolumab
@en
prefLabel
Monitoring PD-L1 positive circ ...... h the PD-1 inhibitor Nivolumab
@en
P2093
P2860
P356
P1433
P1476
Monitoring PD-L1 positive circ ...... h the PD-1 inhibitor Nivolumab
@en
P2093
Angela Gradilone
Chiara Nicolazzo
Cristina Raimondi
Enrico Cortesi
Flavia Longo
Gabriella Del Bene
Maria Mastromartino
MariaLaura Mancini
Orietta Gandini
Paola Gazzaniga
P2860
P2888
P356
10.1038/SREP31726
P407
P577
2016-08-24T00:00:00Z
P6179
1041402830